NCT07216976

Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 62 (estimated)
• Sponsor: MedtronicNeuro · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to evaluate the effectiveness of the Medtronic Adaptive DBS therapy (aDBS) for Parkinson's Disease in China with the Percept family of Implantable Neurostimulators (Percept PC and Percept RC).

Detailed description

The ADAPT-PD China Study will utilize both Dual and Single Threshold aDBS modes (algorithms). Prospective, multicenter, open label comparison (with single-blind aDBS mode from aDBS randomization to evaluation phase), single arm clinical trial designed to evaluate the effectiveness of the Medtronic Adaptive DBS therapy (aDBS) for Parkinson's Disease in China with the Percept family of Implantable Neurostimulators (Percept PC and Percept RC). The study is expected to be conducted at approximately 5 centers located in China.

Conditions

• Parkinson's Disease

Interventions

Type	Name	Description
DEVICE	Percept™ PC and Percept RC with Adaptive DBS (aDBS™)	Subjects for whom meet the LFP screening criteria and can be acceptably configured on the "Best" aDBS mode (Dual or Single Threshold) will receive "Best" Mode aDBS treatment and enter the aDBS Evaluation Phase.

Timeline

• Start date: 2025-11-19
• Primary completion: 2027-01-01
• Completion: 2028-01-01
• First posted: 2025-10-15
• Last updated: 2026-03-11

Locations

5 sites across 1 country: China

Regulatory

• FDA-regulated device study